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Abstract 
In this work the film method (FM), reverse-phase evaporation (REV) and the heating 
method (HM) were applied to prepare PEG-coated liposomes of oxaliplatin with natural 
neutral and cationic lipids, respectively. The formulations developed with the three 
methods, showed similar physicochemical characteristics, except in the loading of 
oxaliplatin, which was statistically lower (P<0.05) using the HM.  
The incorporation of a semi-synthetic lipid in the formulation developed by FM, 
provided liposomes with a particle size of 115 nm associated to the lowest 
polydispersity index and the highest drug loading, 35%, compared to the other two 
lipids, suggesting an increase of the membrane stability. That stability was also 
evaluated according to the presence of cholesterol, the impact of the temperature, and 
the application of different cryoprotectans during the lyophilization. The results 
indicated long-term stability of the developed formulation, because after its intravenous 
in-vivo administration to HT-29 tumor bearing mice was able to induce an inhibition of 
tumor growth statistically higher (P < 0.05) than the inhibition caused by the free drug.  
In conclusion, the FM was the simplest method in comparison with REV and HM to 
develop in vivo stable and efficient PEG-coated liposomes of oxaliplatin with a loading 
higher than those reported for REV.  
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Introduction 
Liposomes are considered as efficient carriers for drugs, vaccines, nutrients, diagnostics, 
and other biomolecules [1-6]. This is due to some advantages, such as the ability to 
incorporate water and lipid soluble agents, high versatility in terms of fluidity of 
liposomal membrane, size and superficial charge [7]. The new generation of liposomes 
by the insertion of polyethylene glycol (PEG) derivatized phospholipids into liposomal 
membrane, leads to obtain sterically stabilized liposomes [3, 8-10]. The main 
characteristics of these liposomes are the decrease of their clearance [11, 12] and their 
increased accumulation in affected organ sites [13, 14]. Therefore, this system is able to 
alter the pharmacokinetics and biodistribution of the encapsulated drug [15]. In this 
way, oxaliplatin is a third generation of platinum (Pt), antitumor drug used as a first-line 
chemotherapy for metastatic colorectal cancer [16-19]. This Pt derivative shows higher 
tolerability of adverse effects than cisplatin or carboplatin [20-22]. However, its 
efficacy is relatively low due to its pharmacokinetics properties, such as high 
irreversible binding to plasmatic and tissue proteins and erythrocytes, among other 
components. For this reason, the encapsulation of oxaliplatin represents a strategy to 
overcome these limitations, delivering in a selective manner the drug into the tumor.  
On the other hand, the methods used to prepare liposomes have a significant impact in 
some physicochemical characteristics such as size or efficiency of encapsulation of the 
agent. In this way, Film method (FM) [23] and Reverse-Phase Evaporation (REV) 
method [24], have been selected by several authors as two conventional methods to 
prepare liposomes. However, in the last years other methods have been described in 
literature, one of them is the Heating method (HM) [25]. This new method is 
characterized by the absence of organic solvent for the solubilization of lipids, 
representing an advantage in terms of toxicity. In general, all methods have advantages 
and disadvantages. 
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FM is characterized by the fact that it can be used for all different types of lipid 
combinations and it is very easy to perform. The main step is the hydration of the lipids, 
and the acceptable encapsulation rates that can be obtained [26]. For REV the main step 
is in the oil/water emulsion which is diluted with further aqueous phase for liposomes 
formation. This method is very popular due to a high encapsulation rate, up to 50%, 
however the problem is the remaining solvent and the high polydispersity index (PDI) 
in the particle size. In both cases, to formulate a homogeneous population of liposomes 
regarding the particle size, it needs the application of a homegenization technique. 
Finally, the HM has not been widely applied, because few examples are only reported in 
the literature with 5-FU and DNA [27-29]. 
Taking into account that most of the publications about liposomes of oxaliplatin have 
used REV method, the aim of this work is the development of PEG-coated liposomes of 
oxaliplatin using different methods and lipids. It is also evaluated the stability of the 
formulation under different conditions. In addition, the cytotoxicity and antitumor 
effects, respectively were assayed in in-vitro and in-vivo models with colorectal cancer 
cell lines. 
 
Material and methods 
Materials 
Oxaliplatin were purchased from Sigma (Barcelona, Spain). Phosphatidylcholine (PC), 
cholesterol (Chol), soy hydrogenated L-α-phosphatidylcholine (HSPC), 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG2000) 
were purchased from Avanti polar lipids Inc. (Alabaster, Alabama, USA). 
Methods 
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Oxaliplatin liposomes preparation 
Three different methods were carried out to develop oxaliplatin loaded liposomes. 
Film  Method 
Liposomes containing oxaliplatin were prepared employing the thin film hydratation 
method following the basic specifications described by Bangham et al [23]. Briefly, 
lipids were dissolved in chloroform forming a mixture. The organic solvent was then 
removed by rotary evaporation under reduced pressure (Büchi-R144, Switzerland) at 
room temperature (RT) to obtain a film on the wall of the flask. The dry lipid film was 
hydrated with a solution of oxaliplatin dissolved in glucose 5% (2 mg/ml). The 
dispersion of the lipid was facilitated by mechanical shaking in an ultrasound bath for 1 
min. To control the particle diameter, the emulsion was extruded through a 
polycarbonate membrane (Mini-Struder Set, Avanti Polar Lipids Inc (Albaster, 
Alabama, USA)) with a pore size of 100 nm.  
Reverse Phase Evaporation Method 
This method, described by Szoka and Papahadjopoulos [24], is used to prepare 
liposomes with a large internal aqueous space. Lipids solubilized in a mixture of 
chloroform:diethyl ether (1:2, v/v) were added to the aqueous phase containing 
oxaliplatin (4 mg/mL) dissolved in glucose 5%, in a ratio 3:1 (v/v) between organic and 
aqueous phase. The mixture was sonicated at RT for 5 min, and placed on the rotary 
evaporator to remove the organic solvent under reduced pressure (200 mm Hg). At this 
point, the material forms a viscous gel, which becomes an aqueous suspension by 
shaking in a vortex. The liposomes were extruded following the method described 
above. 
Modified Heating Method  
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In the last technique, the heating method [25] was combined with a gradient of pH [30].  
The lipids were hydrated in a citrate solution (pH 4), and mixed in a bath-ultrasound for 
1 min. The mixture was extruded as it has been described in the previous methods, and 
the excess of citrate was removed by ultrafiltration (Amicon with a cut-off membrane of 
10,000 MWCO membrane, Millipore, Billerica, USA). The incorporation of oxaliplatin 
(2 mg/mL) dissolved in glucose 5% was achieved by adding the drug solution together 
with Hepes solution (pH 7.8). This mixture was heated at the corresponding lipids 
transition temperature 60º C for 30 min. Afterwards, it was cooled at 4º C.  
In all methods the amount of non-encapsulated oxaliplatin was removed from the 
formulation by ultrafiltration using the Amicon devices (10,000 MWCO) The final 
formulation was washed, at least two times, with 3 ml of PBS and ultrafiltered again. To 
evaluate the efficiency of this method, a constant concentration of free oxaliplatin (1mg/mL) 
was added to empty liposomes. This mixture was shaking for 30 min at room temperature, 
and it was ultrafiltered using the Amicon system (10,000 MWCO) at 2,200 g for 30 
min. After the ultrafiltration, both aliquots were collected, the liposomes and the ultra-
filtered solution, to measure the levels of oxaliplatin by the atomic absorption 
spectrometry technique. Liposomes without oxaliplatin, empty formulation, were 
prepared following the same procedure but adding glucose 5%. 
These methods were carried out with two different types of lipids neutral, such as PC 
and cationic, DOTAP, in order to study the influence of them in the physicochemical 
characteristics of the liposomes developed, and in the efficiency of encapsulation (EE) 
of oxaliplatin.  
Characterization of liposomes 
The particle size, polydispersity index (PDI) and Zeta potential of liposomes were 
analyzed by laser diffractometry using a Zetasizer Nano-Z (Malvern Instruments, UK). 
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Formulations were diluted 1:100 (v/v) in deonized water in order to ensure a convenient 
scattered intensity on the detector. 
The oxaliplatin encapsulation was measured by atomic absorption spectrometry using a 
validated method. Then, the EE expressed in percentage (%), was calculated by dividing 
the drug to lipid ratio recovered after ultrafiltration in the final formulation by the initial 
amount of oxaliplatin and lipid. 
The phospholipid concentration was quantified following the Zöllner and Kirsch 
method [31]. 
Stability of liposome formulations 
Stability is a critical factor that must be considered during formulation design and 
development. Physical or colloidal stability based on size distribution under storage 
conditions as well as in a biological medium, must be considered. Based on the results 
found during liposome formulation, HSPC-liposomes developed with FM were selected 
to characterize the stability of the liposomes formulated without and with cholesterol 
[HSPC:Chol:DSPE-PEG2000]. Chol was used at 40% in the lipid mixture.  
In addition, other different approaches were followed to complete this study: 
• Drug release 
This study was carried out at two different temperatures, 4ºC used to storage the 
formulation, and 37 ºC used for in-vitro and in-vivo studies. Then, 100 µl of formulation 
mixed with 900 μl of complete cell medium was incubated at 37ºC in continuous 
shaking. Samples collected at different times: 0, 1, 4, 7 and 24 h, were ultrafiltered 
using the Amicon system (10,000 MWCO) to obtain the liposomes. The encapsulated 
and released oxaliplatin levels were quantified by atomic absorption spectrometry. In 
addition the parameters, particle size, PDI and Zeta potential, were also characterized in 
these samples. 
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•  Lyophilization assay 
Formulations were lyophilized following three different strategies: without  
cryoprotectant, with Trehalose (4:1,w/w sugar: lipid), or with L-arginine (4:1, w/w 
aminoacid: lipid). After the lyophilization process, the formulation was again 
characterized by determining size, PDI and Zeta potential. 
Transmission electron microscopy (TEM) 
Liposomes formulated without and with DSPE-PEG2000 were analyzed by TEM [32]. 
The measurements were carried out by means of a LIBRA-Zeiss 120 electron 
microscope operating at 80 kV, equipped with an electron spectrometer filtering out 
inelastic electrons for better imaging. 10 µl of the sample was incubated with OsO4 1% 
during 30 minutes. 20 µl of the mixture was deposited over carbon-coated copper grids 
with 200 mesh during 60 seconds and dried. Negative contrast staining was done with 
2% aqueous phosphotungstic acid solution. The samples were visualized 24 hours later. 
The same protocol was followed for the negative control corresponding to a sample 
without liposomes. Images were analyzed with iTEM Olympus Soft Imaging Solutions 
GmbH 5.1 software. 
Antiproliferative activity in cultured cells 
The human colorectal cancer lines HCT-116 and HT-29 (purchased from ATCC) were 
cultured in McCoy's  Medium Modified, completed with Fetal Bovine Serum (10%) and 
Penicillin-Streptomicin (0.01%), at 37ºC in a humidified atmosphere containing 5% 
CO2. All cells were used under sub-confluence condition. 
Cells were seeded into 96-well microtiter plates at a density of 10× 103 cells/well/200 μl 
of medium. After 24 h, cells were treated with several concentrations (ranged from 0.1 
to 50μM) of free oxaliplatin, empty liposomes or oxaliplatin liposomes for 72 h. The 
 8
survival cells after each treatment were measured with the colorimetric Neutral Red 
Assay [33]. The optical density was read at 540 nm (Labsystems iEMS Reader MF).  
In vivo study 
Twenty four female athymic nude mice weighing 20-25 g (aprox. 4 weeks old) were 
purchased from Harlan (Barcelona, Spain). Animals were housed in microisolator cages 
under positive-pressure ventilation and maintained in closed-shelf, laminar-flow racks 
to avoid contact with pathogens, odors or noises and kept under standard laboratory 
conditions. Sterilized food and water were available ad libitum. 
To induce the tumor, 100 μl of PBS containing 1.5 x 106 HT-29 cells were 
subcutaneously injected into the right flank of the mice. Tumor growth expressed as 
volume (V) was calculated by V = 4/3 π (A2B/2), where A and B correspond to the 
smallest and the largest diameter, respectively [34]. One week after cells injection and 
when the volume of the tumor was around 200 mm3, animals were randomly divided 
into four groups with 6 animals per group: Group I, control (PBS), Group II, animals 
treated with empty liposomes at corresponding dose of oxaliplatin, Group III, free 
oxaliplatin (5 mg/kg) and Group IV, oxaliplatin encapsulated in liposomes (5 mg/kg). 
The dose of liposomes was calculated based on the μg of oxaliplatin encapsulated per 
mg of lipid, avoiding a concentration higher than 1.25 mg of lipids in each injection. All 
animals received 2 consecutives cycles of treatment with 5 days apart. In each of them, 
two doses of 2.5 mg/kg every 48 h were administered. At the end of the study, animals 
were sacrificed by cervical dislocation. The tumor was removed to quantify the 
oxaliplatin levels. This organ was weighted and homogenized with nitric acid 0.1 N 
overnight (100 mg tissue/1mL acid) and diluted with 5mL of deonized water. Then, the 
samples were measured by atomic absorption spectrometry. Toxicity was also evaluated 
by measuring the body weight at the same time that the tumor. 
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The protocol of the study was approved by the Animal Experimentation Committee of 
the University of Navarra and is in accordance with the applicable European guidelines. 
Statistical analysis 
The results were expressed as the mean ± standard deviation (SD). The statistical study 
was performed using SPSS, version 15.0 for windows. All data were analyzed with the 
non-parametric Kruskall-Wallis test followed by the Mann-Whitney U test. The level of 
significance was set at P < 0.05.  
 
Results 
Characterization of  PEG-coated liposomes of Oxaliplatin 
Film Method 
The results found with FM are shown in Table 1. The particle size was similar to two 
formulations as it was expected, due to the use of the extrusion technique with the same 
type of membrane. The Zeta potential was negative for PC, due to the combination of 
PEG and positive for DOTAP, a typical cationic lipid. In relation to the EE, the 
percentages were similar between both lipids, although it was slightly higher for PC 
than for cationic lipid (P>0.05). However, this value was higher than those reported by 
other authors [35-38]. 
Reverse Phase Evaporation Method 
REV is the most common technique used to encapsulate platinum derivatives. Table 1 
shows the results found for liposomes of oxaliplatin, where all parameters were very 
similar for both lipids, except the Zeta potential, as it was expected. The EE for drug 
was slightly lower for DOTAP, but this difference was not significant (P>0.05), 
suggesting that the method ruled in the same way with independence of the ionic charge 
of the lipid.  
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Heating Method Modified 
This method has been modified adding citrate and Hepes buffers to reach a gradient of 
pH. This change was because the amount of oxaliplatin incorporated into liposomes 
without difference of pH between inside-outside, was very low, 6% approximately. 
However, when the oxaliplatin was in a solution of pH 7.8, the encapsulation rate was 
higher than 20%. Although the size and Zeta potential obtained in these formulations, 
were similar to those observed with the other two methods, and the EE was lower 
(P<0.05) (Table 1). 
No differences were observed between liposomes with vs. without oxaliplatin in each of 
the methods (data not shown). 
The three methods can be considered for manufacturing liposomes of oxaliplatin. 
However the REV was one of the most complex due to the number of steps. In fact, 
several initial conditions of oxaliplatin/lipid ratio were tested to increase the loading, 
but this value did not increase when the amount of oxaliplatin was higher than 4 
mg/mL. In addition, the liposome suspension showed quite high polydispersity in terms 
of size. The reason could be that to obtain homogeneous population of liposomes the 
extrusion technique could be applied with two types of membranes before the 
evaporation step.  
On the other hand, although HM has the advantage to produce liposomes without 
volatile organic solvents to dissolve the lipids, the EE for oxaliplatin was the lowest 
compared to FM or REV. The main step is the incorporation of the drug into the 
liposomes previously formulated by heating at temperatures not lower than the 
transition temperature (Tc) of the lipids. This Tc was around 60º C, which is not high 
enough to modify the stability of the platinum molecule. 
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Based on the results found in Table 1, the FM appeared to be the simplest method to 
prepare liposomes with an adequate size, PDI and EE of oxaliplatin. Since PC and 
DOTAP were used as two basic lipids for selecting the method, another semisynthetic 
hydrogenated lipid, HSPC, was included. This lipid was of interest because is one of the 
main components of several marketed liposomal formulations. Lipids with different 
degree of saturation in their aliphatic chain seem to provide a higher stabilization effect 
to the liposomal membrane. The physicochemical parameters of this formulation were 
similar to those obtained for the liposomes formulated with PC. Thus, the particle size 
for this formulation was 115.6 ± 2.0 nm, with a Zeta potential of -18.4 ± 3.9 mV, the EE  
was 34.23 ± 2.9 % and a loading of 68.5 ± 4.2 μg /mg lipid. Moreover, the PDI was 
lower than the PC formulation, 0.034 ± 0.01 vs. 0.161 ± 0.02, suggesting that HSPC 
contributed to increase the stabilization of the membrane. Therefore HSPC-DSPE-
PEG2000 liposomes were selected for the next studies. 
 Stability assay 
Previous studies showed that at 4 ºC the formulations were stable in relation to size, 
Zeta potential and EE, at least for one month. The impact of several factors such as the 
inclusion of Chol, the temperature, different solutions for the incubation and freeze-
drying processes, was also investigated to evaluate the retention of oxaliplatin into the 
liposomes. Table 2 shows that at 37ºC the inclusion of the sterol increased the stability 
of the membrane, although the difference in the retention of oxaliplatin between both 
formulations, with vs. without Chol, was only 10%. However, the drug release in the 
culture cell medium was slower for liposomes with Chol, suggesting that this release 
takes time, because Chol is able to stabilize the lipid bilayers. Therefore, a depot effect 
in tumor area could be achieved using this PEGylated liposomal formulation. This 
effect represents an advantage to oxaliplatin because, the drug would be more stable in 
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the blood circulation and could be released slowly at the tumor site. In addition, the PDI 
had a higher value for liposomes without Chol. This observation is compatible with an 
aggregation of the particles.  
Since the structural integrity of the liposomes for long period of time is one of the 
objectives to optimize the formulation, the effect of the dehydration/reconstitution 
process was assayed in this work. Two different cryoprotectants, Trehalose and L-
arginine were used to prevent the thermodynamic instability evaluated by the changes in 
the size and Zeta potential. L-arginine was included with the thought of the possible 
problems of diabetic patients. The results listed in Table 3, showed that the presence in 
the formulation of Chol together with Trehalose or L-arginine, was the best combination 
to obtain a stable formulation. Both cryoprotectans displayed similar behaviour, 
supporting the fact that both could be used.  
Transmission electron microscopy (TEM) 
Figure 1 shows that HSPC:Chol of liposomes were small vesicles with a concentric 
interior space. In the case of liposomes associated with DSPE-PEG2000, a white coated 
film was observed in the surface [32]. 
Cytotoxic studies in colon cancer cell lines 
The two cell lines were sensitive for oxaliplatin with IC50 values between 9.2-2.8 μM 
for the free drug. Oxaliplatin-loaded liposomes showed a reduced cytotoxicity. This 
effect was observed for the three types of lipids used in the formulation. Table 4 lists the 
IC50 values found for all treatments in both cell lines, HT-29 and HCT-116. HCT-116 
was more sensitive to oxaliplatin, free and encapsulated, than HT-29. The cytotoxic 
effect was higher in both cell lines for free than for the encapsulated oxaliplatin in 
anionic liposomes, PC LP and HSPC LP. However in the case of the cationic liposomes, 
the value of the IC50 was very similar to the value for the free drug. This difference 
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could be explained by the effect of the empty DOTAP liposomes. They were able to 
reduce the proliferative effect to 30 % compared to the control group. PC and HSPC 
liposomes without oxaliplatin did not affect the cell proliferation. 
In vivo study 
The formulation, [HSPC:Chol:DSPE-PEG2000]-oxaliplatin liposomes, was intravenously 
administered to HT-29 tumor bearing mice. The dose was selected based on previous 
results found in our group (data not shown) and on the dose reported by Abu-Lila et al 
[35-37], although the cell lines were not the same. Figure 2 shows that PEGylated 
liposomes suppressed tumor growth more efficiently than free oxaliplatin. This 
inhibition reached statistical significance (P<0.05) during the second cycle. This 
enhanced anti-tumor activity of the liposomes is in line with those results reported by 
several authors for different antitumor drugs encapsulated in PEGylated liposomes. The 
levels of oxaliplatin found in the tumor at the end of the study, were three times higher 
for encapsulated drug in comparison with free drug: 560 ± 200 vs. 190 ± 101 ng/ mg 
tissue, respectively. In addition, this dose schedule was compatible with a low toxicity 
for both treatments (Figure 3). So, the encapsulation of oxaliplatin exhibited an 
improvement in the therapeutic effect of the drug.  
Discussion 
In this work PEGylated liposomes of oxaliplatin have been developed using different 
methods. FM and REV were selected as the most common methods used to prepare 
conventional liposomes [4-5]. The HM was chosen as one of the novel methods, 
introduced in the last years. The absence of volatile organic solvents in this last method 
is the main characteristic. It represents a potential benefit in relation to the toxicity 
exerted by these components in in vivo [25]. In addition two types of lipids have been 
used to evaluate their influence in the physicochemical characteristics of the 
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formulations obtained for each type of method. The results showed that the lipid did not 
have any influence in the studied characteristics. However, in the case of the REV 
method, the particle size was slightly higher than in the FM and HM, even when all 
methods were associated to the extrusion technique with the same type of polycarbonate 
membrane. This difference could be explained by the fact that, REV is one of the most 
complex methods compared to FM and HM. For example, the main step is the 
formation of a viscous gel which is responsible of the spontaneous formation of 
liposomes dispersion [24]. The characteristics of these liposomes depend on the mixture 
(lipid-water) in the emulsion and the time for the evaporation, among other steps. This 
leads to a higher variability in the final formulations than with the other two methods, 
which are methodologically simpler.  
In the case of the HM, the encapsulation of oxaliplatin dissolved in glucose 5%, was 
extremely low (aprox. 6%). However, when a gradient of pH was reached between 
inside (pHi 4) and outside (pHo 7.8) of the liposomal formulation, the efficiency of 
encapsulation achieved levels of 20%. This result is in the same order as those values 
reported by other authors for oxaliplatin using the REV method [35-38]. In general, the 
transbilayer transport of weak acids and weak bases is more efficient in the presence of 
a pH gradient, but little or none encapsulation is observed in the absence of this gradient 
[30], as it was demonstrated for doxorubicine. 
Finally, the FM associated with the extrusion technique allowed the formulation of an 
homogenous population of liposomes following very simple steps. Although some 
liposomal formulations with other antitumor drugs have been developed using this 
method, in the case of oxaliplatin most of them have been formulated with REV. The 
main advantage of this method is the encapsulation rate which can be up to 50%. 
Nevertheless, a significant difference is found in relation to the particle size and EE of 
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oxaliplatin depending on the author. For example, with REV and neutral lipids, Abu 
Lila et al [35-37] have reported liposomes with a particle size of 200 nm and an EE of 
20 %, higher than the EE found by Suzuki et al [38]. In the last year, Yang et al [39] 
have described the methodology to develop PEG-liposomes of oxaliplatin with a 
particle size of 150 nm, and an EE of 40%. Note that this value has not been described 
how it was calculated. 
In this work, the particle size was reduced to 115.3 ± 3.5 nm obtaining an EE of 34.2 ± 
2.9 %. This loading drug was calculated as Abu Lila and coworkers have described. 
Although several concentrations of oxaliplatin (2, 4 and 5 mg/mL) were assayed, the 
loading did not change between 4 and 5 mg/mL. 
On the other hand, different techniques have been found in the literature for the removal 
of the non-encapsulated drug: the dialysis technique against 5% of dextrose [35-37] or 
the ultrafiltration [39]. In our study the applied ultrafiltration technique showed that the 
99.72% of the free drug added to empty liposomes, was in the ultrafiltered solution 
justifying its use. 
The three methods have similar behaviour for neutral and cationic lipids, as it was 
previously reported by Abu-Lila et al. [40]. This data shows that each method to 
encapsulate a specific drug, had a similar behaviour with a non-dependence of the 
superficial charge of the lipid. 
Taking into account that the formulations obtained with the three methods were very 
similar, the FM was selected to study several factors that influence the stability of the 
formulations. One of them is the use of semisynthetic lipid such as HSPC, a component 
of many marketed liposomal formulations such as, Doxil or Caelyx for doxorubicin 
(HSPC/Chol/DSPE-PEG2000); Ara-c (HSPC/Chol/DSPE-PEG2000); Lurtotecan 
(HSPC/Chol); Ambisome (HSPC/Chol/DSPG) [5, 41, 42]. Although the 
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physicochemical characteristics of HSPC liposomes were similar to those found for PC, 
the PDI was lower and the EE slightly higher. The degree of saturation of the aliphatic 
chain of the lipid confers a more dynamic structure of the membrane. This property 
should represent an advantage for entrapping more of the drugs with a low permeability 
across the cellular membranes, as in the case with oxaliplatin [7].  
Finally, HSPC-LP was selected to study other factors that influence the stability of the 
formulation. These factors were the temperature at 37 ºC, the medium of the liposomes 
incubation, and the presence of Chol in the membrane. In the case of the incorporation 
of Chol, this factor did not influence significantly the amount of oxaliplatin released 
from the formulation. After 24 h of incubation at 37ºC, both types of formulations with 
and without sterol, release oxaliplatin with a difference of 10%. This difference in drug 
concentration suggests a minimum impact in the effect. Nevertheless, the most 
important aspect in the in-vivo activity is the time-release of the drug. Therefore, this 
point could be a limitation for the formulation for further studies. In this work, the 
retention time of oxaliplatin into the formulation assayed in culture cell medium was 
slightly higher than the value found by Abu Lila et al. [37] in plasma. Plasma does not 
have the same compositions of culture cell medium, but its complexity suggests that the 
behaviour of the formulation could be similar to plasma.  
Then, the Chol exerted its function as a stabilizing agent of the liposomal membrane, 
which was reflected in the lower PDI compared to the PDI of formulations without 
Chol. Therefore, the final formulation using the mixture HSPC:Chol:DSPE-PEG2000 
was selected to assay its  in-vivo activity. 
The results found with the lyophilisation technique represent a promising strategy to 
provide a stable formulation for a long period of time. Sugars have been reported to act 
as protective agents during the dehydration/reconstitution of liposomes by preventing 
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vesicle fusion and enhancing the retention of the encapsulated compounds within the 
liposomes [43-46]. Because amino acids exhibite similar lypoprotective effect as sugars, 
L-arginine was assayed regarding the problems for diabetic patients [47]. The 
application of amino acids or sugars as potential cryoprotectants did not show 
significant differences, although in both cases, the presence of Chol lead to a marked 
stability of liposomes during the freeze-drying process. This effect has been previously 
reported by Popova and Hincha (2007) [48]. They have reported an interaction between 
phospholipids and sugars due to the presence of Chol. This sterol could increase the 
lipid space leading the sugars to interact with lipid head-groups. Nevertheless, more 
studies are required to optimize the use of cryoprotectants in the lyophilisation of 
liposomes, because the EE of the reconstituted liposomes decreased in 6.1 ± 2.9 %. 
The in-vitro antitumor activity showed that HCT-116 had a higher sensibility to 
oxaliplatin compared to HT-29. This result was supported by Kalimutho et al. [49], 
because they have reported that the status of p-53, wild-type in HCT-116 and mutated in 
HT-29, could be involved in this phenomenon explaining that difference. In this study, 
the free oxaliplatin led to a better antiproliferative effect than the encapsulated (Table 
4).  These results are according to the results reported by several authors regarding the 
IC50 for free drug vs. liposomal formulation [50]. In the case of the cationic formulation, 
its effect could be explained by the additional cytotoxicity found for empty liposomes 
discarding these liposomes for further studies. Additionally, the in- vivo toxicity of 
DOTAP liposomes have been reported in the literature [51, 52].  
On the other hand, the in-vivo study carried out with the HSPC:Chol:DSPE-PEG2000 
liposomes,  showed an efficient antitumor activity in the murine tumor-xenograft model, 
reflecting the stability and ability of the formulation to reach the tumor area. This result 
suggests that PEG-coated liposomes could act as a depot of oxaliplatin in the tumor 
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area, delaying its RES uptake due to the presence of the PEG in the surface of 
liposomes [13-15]. The antitumor activity for this formulation was more evident in-vivo 
than in-vitro, which is according to the results found by other authors [38]. Therefore, 
PEG-coated liposomes of oxaliplatin developed by the FM, the simplest method, 
provided a potent antitumor activity compared to the free drug.  
In our knowledge, this is the first study where PEG-coated liposomes of oxaliplatin 
have been developed using several methods, FM, REV and HM to compare the impact 
of them in the physicochemical parameters of the formulations, including the efficiency 
of encapsulation. Moreover, the effect of the inclusion of a semi-synthetic lipid and the 
Chol led to obtain a formulation stable during the incubation at high temperature and 
the lyophilisation process.  
Finally, the in-vivo antitumor efficiency was characterized by a reduction followed by a 
stabilization of the tumor. This effect, together with the oxaliplatin levels found in this 
organ, suggest a long-time stability of the formulation. 
 
References 
[1] F.C. Jr. Szoka, The future of liposomal drug delivery. Biotechnol Appl Biochem. 12 
(1990) 496-500.  
[2] V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers. Nat Rev 
Drug Discov. 4 (2005) 145-160. 
[3] S.M. Moghimi, J. Szebeni, Stealth liposomes and long circulating nanoparticles: 
critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog 
Lipid Res. 42 (2003) 463-78.  
 19
[4] Y. Kaneda, Y. Tabata, Non-viral vectors for cancer therapy. Cancer Sci. 97 (2006) 
348-354.  
[5] R.D. Hofheinz, S.U. Gnad-Vogt, U. Beyer, A. Hochhaus, Liposomal encapsulated 
anti-cancer drugs. Anticancer Drugs. 16 (2005) 691-707.  
[6] L. Brannon-Peppas, J.O. Blanchette, Nanoparticle and targeted systems for cancer 
therapy. Adv Drug Deliv Rev. 56 (2004) 1649-1659. 
[7] J.R. Simard, B.K. Pillai, J.A. Hamilton, Fatty acid flip-flop in a model membrane is 
faster than desorption into the aqueous phase. Biochemistry. 47 (2008) 9081-9089. 
[8] T.M. Allen, C. Hansen, F. Martin, C. Redemann, A. Yau-Young, Liposomes 
containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged 
circulation half-lives in vivo. Biochim Biophys Acta. 1066 (1991) 29-36. 
[9] B. Romberg, W.E. Hennink, G. Storm, Sheddable coatings for long-circulating 
nanoparticles. Pharm Res. 25 (2008) 55-71. 
[10] H. Song, J. Zhang, Z. Han, X. Zhang, Z. Li, L. Zhang, M. Fu, C. Lin, J. Ma, 
Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. Cancer 
Chemother Pharmacol. 57 (2006) 591-598. 
[11] M.M. Frank, The reticuloendothelial system and bloodstream clearance. J Lab Clin 
Med. 122 (1993) 487-488.  
[12] A.A. Gabizon, H. Shmeeda, S. Zalipsky, Pros and cons of the liposome platform in 
cancer drug targeting. J Liposome Res. 16 (2006) 175-183. 
 20
[13] J. Fang, H. Nakamura, H. Maeda, The EPR effect: Unique features of tumor blood 
vessels for drug delivery, factors involved, and limitations and augmentation of the 
effect. Adv Drug Deliv Rev. 63 (2011) 136-151. 
[14] K. Greish, Enhanced permeability and retention (EPR) effect for anticancer 
nanomedicine drug targeting. Methods Mol Biol. 624 (2010) 25-37. 
[15] H. Ehrsson, I. Wallin, J. Yachnin, Pharmacokinetics of oxaliplatin in humans. Med 
Oncol. 19 (2002) 261-265. 
[16] A. Ibrahim, S. Hirschfeld, M.H. Cohen, D.J. Griebel, G.A. Williams, R.Pazdur, 
FDA drug approval summaries: oxaliplatin. Oncologist. 9 (2004) 8-12. 
[17] C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh, D. Mery-Mignard, E. 
Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet, A. de 
Gramont, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced 
colorectal cancer: a randomized GERCOR study. J. Clin Oncol. 22 (2004) 229-237.  
[18] S. Nobili, D. Checcacci, F. Filippelli, S. Del Buono, V. Mazzocchi, T. Mazzei, E. 
Mini, Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-
fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with 
irinotecan- or oxaliplatin-based chemotherapy. J Chemother. 20 (2008) 622-631. 
[19] G. Bruera, A. Santomaggio, K. Cannita, P.L. Baldi, M. Tudini, F. De Galitiis, M. 
Mancini, P. Marchetti, A. Antonucci, C. Ficorella, E. Ricevuto, "Poker" association of 
weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-
B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC 
Cancer. 19 (2010) 10-567. 
 21
[20] C.A. Rabik, M.E. Dolan, Molecular mechanisms of resistance and toxicity 
associated with platinating agents. Cancer Treat Rev. 33 (2007) 9-23. 
[21] E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, E. Cvitkovic, Cellular and 
molecular pharmacology of oxaliplatin. Mol Cancer Ther. 1 (2002) 227-35. 
[22] E. Raymond, S. Faivre, J.M. Woynarowski, S.G. Chaney, Oxaliplatin: mechanism 
of action and antineoplastic activity. Semin Oncol. 25 (1998) 4-12. 
[23] J.A. Bangham, E.J. Lea, The interaction of detergents with bilayer lipid 
membranes. Biochim Biophys Acta. 511 (1978) 388-396. 
[24] F. Jr. Szoka, D. Papahadjopoulos, Procedure for preparation of liposomes with 
large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl 
Acad Sci U S A. 75 (1978) 4194-4198. 
[25] M.R. Mozafari, Liposomes: an overview of manufacturing techniques. Cell Mol 
Biol Lett. 10 (2005) 711-719. 
[26] S. Vemuri, C.T. Rhodes, Preparation and characterization of liposomes as 
therapeutic delivery systems: a review. Pharm Acta Helv. 70 (1995) 95-111.  
[27] M.R. Mozafari, C.J. Reed, C. Rostron, C. Kocum, E. Piskin. Formation and 
characterisation of non-toxic anionic liposomes for delivery of therapeutic agents to 
the pulmonary airways. Cell Mol Biol Lett. 7 (2002) 243-244.  
[28] M.R. Mozafari, C.J. Reed, C. Rostron, Cytotoxicity evaluation of anionic 
nanoliposomes and nanolipoplexes prepared by the heating method without 
employing volatile solvents and detergents. Pharmazie. 62 (2007) 205-209. 
 22
[29] S.M. Mortazavi, M.R. Mohammadabadi, K. Khosravi-Darani, M.R. Mozafari, 
Preparation of liposomal gene therapy vectors by a scalable method without using 
volatile solvents or detergents. J Biotechnol. 129 (2007) 604-613. 
[30] P.R. Cullis, M.J. Hope, M.B. Bally, T.D. Madden TD, L.D. Mayer, D.B. Fenske, 
Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and 
metal ions into large unilamellar vesicles. Biochim Biophys Acta. 1331 (1997) 187-
211.  
[31] N. Zöllner, G. Wolfram, W. Londong, K. Kirsch, Study of plasma lipids in 
newborn infants, infants and young children Klin Wochenschr. 44 (1996) 380-386. 
[32] M. Mockey, E. Bourseau, V. Chandrashekhar, A. Chaudhuri, S. Lafosse, E. Le 
Cam, V.F. Quesniaux, B. Ryffel, C. Pichon, P. Midoux, mRNA-based cancer vaccine: 
prevention of B16 melanoma progression and metastasis by systemic injection of 
MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 14 (2007) 802-814.  
[33] C. W. Löwik, M.J. Alblas, M. van de Ruit, S.E. Papapoulos, G. van der Pluijm. 
Quantification of adherent and nonadherent cells cultured in 96-well plates using the 
supravital stain neutral red. Anal Biochem. 213 (1993) 426-433. 
[34] Y.L. Lee, H.J. Kim, M.S. Lee, J.M. Kim, J.S. Han, E.K. Hong, M.S. Kwon, M.J. 
Lee, Oral administration of Agaricus blazei (H1 strain) inhibited tumor growth in a 
sarcoma 180 inoculation model. Exp Anim. 52 (2003) 371-375. 
[35] A.S. Abu Lila, T. Suzuki, Y. Doi, T. Ishida, H. Kiwada Oxaliplatin targeting to 
angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a 
dorsal air sac mouse model. J Control Release. 134 (2009) 18-25. 
 23
[36] A.S. Abu Lila, S. Kizuki, Y. Doi, T. Suzuki, T. Ishida, H. Kiwada, Oxaliplatin 
encapsulated in PEG-coated cationic liposomes induces significant tumor growth 
suppression via a dual-targeting approach in a murine solid tumor model. J Control 
Release. 137 (2009) 8-14. 
[37] A.S. Abu Lila, Y. Doi, K. Nakamura, T. Ishida, H. Kiwada, Sequential 
administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a 
significant delivery of subsequent dose into murine solid tumor. J Control Release. 
142 (2010) 167-173.  
[38] R. Suzuki, T. Takizawa, Y. Kuwata, M. Mutoh, N. Ishiguro, N. Utoguchi, A. 
Shinohara, M. Eriguchi, H. Yanagie, K. Maruyama, Effective anti-tumor activity of 
oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm. 346 (2008) 143-
150.  
[39] C. Yang, H.Z. Liu, Z.X. Fu, W.D. Lu, Oxaliplatin long-circulating liposomes 
improved therapeutic index of colorectal carcinoma. BMC Biotechnol. 15 (2011) 11-
21. 
[40] A.S. Abu Lila, T. Ishida, H. Kiwada, Targeting anticancer drugs to tumor 
vasculature using cationic liposomes. Pharm Res. 27 (2010) 1171-1183. 
[41] W.C. Zamboni, Liposomal, nanoparticles and conjugated formulations of 
anticancer agents. Clin. Cancer Res. 11 (2005) 8230-8234. 
[42] D.B. Fenske, P.R. Cullis, Liposomal nanomedicine. Expert Opin. Drug Deliv. 5 
(2008) 25-44. 
 24
[43] L.M. Crowe, J.H. Crowe, A. Rudolph, C. Womersley, L. Appel, Preservation of 
freeze-dried liposomes by trehalose. Arch Biochem Biophys. 242 (1987) 240-247. 
[44] C. Chen, D. Han, C. Cai, X. Tang, An overview of liposome lyophilization and its 
future potential. J Control Release. 142 (2010) 299-311.  
[45] D. Christensen, C. Foged, I. Rosenkrands, H.M. Nielsen, P. Andersen, E.M. Agger, 
Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-
drying. Biochim Biophys Acta. 1768 (2007) 2120-2129. 
[46] C.S. Pereira, R.D. Lins, I. Chandrasekhar, L.C. Freitas, P.H. Hünenberger, 
Interaction of the disaccharide trehalose with a phospholipid bilayer: a molecular 
dynamics study. Biophys J. 86 (2004) 2273-2285 
[47] A.R. Mohammed, A.G. Coombes, Y. Perrie, Amino acids as cryoprotectants for 
liposomal delivery systems. Eur J Pharm Sci. 30 (2007) 406-413. 
[48] A.V. Popova, D.K. Hincha, Effects of cholesterol on dry bilayers: interactions 
between phosphatidylcholine unsaturation and glycolipid or free sugar. Biophys J. 93 
(2007) 1204-1214. 
[49] M. Kalimutho, A. Minutolo, S. Grelli, A. Formosa, G. Sancesario, A. Valentini, G. 
Federici, S. Bernardini, Satraplatin (JM-216) mediates G2/M cell cycle arrest and 
potentiates apoptosis via multiple death pathways in colorectal cancer cells thus 
overcoming platinum chemo-resistance. Cancer Chemother Pharmacol. 67 (2010) 
1299-1312. 
[50] T. Tippayamontri, R. Kotb, B. Paquette, L. Sanche, Cellular uptake and 
cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal 
 25
formulation in human colorectal cancer cells HCT116. Invest. New. Drugs, 29 (2011) 
1321-1327. 
[51] M.C. Filion MC, N.C. Phillips, Toxicity and immunomodulatory activity of 
liposomal vectors formulated with cationic lipids toward immune effector cells. 
Biochim Biophys Acta. 1329 (1997) 345-356. 
[52] J.D. Tousignant L.A. Gates, L.A. Ingram, C.L. Johnson, J.B. Nietupski, S.H. 
Cheng, S.J. Eastman, R.K. Scheule, Comprehensive analysis of the acute toxicities 
induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. 
Hum Gene Ther. 11 (2000) 2493-2513. 
 26
Legends to figures. 
 
Figure 1. Transmission electron microscope photograph. Left panel shows non-
pegylated liposomes (HSPC:Chol (2:1)), whereas right panel shows pegylated-
liposomes (HSPC-Chol-PEG2000 (2:1:0.2)). Bars represent 100 nm. The negative control 
is in the low panel. 
Figure 2. Time profiles of the  tumor growth after two cycles of treatments with free 
and encapsulated oxaliplatin. Each symbol represent the mean of six animals and the 
bars the corresponding standard deviation. Oxal-LP, liposomes of oxaliplatin; Oxal-
free, oxaliplatin in solution and Empty-LP, liposomes without oxaliplatin. (*P<0.05) 
Figure 3. Body weight changes in mice treated with PBS (control), empty liposomes, 




PC: Phosphatidylcholine; HSPC: soy hydrogenated L-α-phosphatidylcholine; DOTAP: 
1,2-dioleoyl-3-trimethylammonium-propane; DSPE-PEG200: 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000]; Chol: 
cholesterol; PDI: Polydispersion index; EE: encapsulation efficacy; LP: liposome; REV: 
Reverse Phase Evaporation; FM: Film Method; HM: Heating Method; RT: Room 
temperature; TC: Transition temperature; FBS: Fetal bovine serum; ED: Encapsulated 
drug; pHi: internal pH; pHo: outside pH; 5-FU: 5-fluorouracil. 
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